Philly Risperdal Verdict Spells Trouble For J&J
The $2.5 million verdict in a Philadelphia bellwether trial over a Johnson & Johnson unit's failure to warn about the risk of male breast growth associated with the antipsychotic drug Risperdal...To view the full article, register now.
Already a subscriber? Click here to view full article